Description: aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Home Page: www.atyrpharma.com
10240 Sorrento Valley Road
San Diego,
CA
92121
United States
Phone:
858 731 8389
Officers
| Name | Title |
|---|---|
| Dr. Sanjay S. Shukla M.D., M.S. | President, CEO & Director |
| Ms. Jill M. Broadfoot CPA | Chief Financial Officer |
| Ms. Nancy E. Denyes Krueger J.D. | General Counsel & Corporate Secretary |
| Xiang-Lei Yang Ph.D. | Founder |
| Dr. Jayant Aphale MBA, Ph.D. | Vice President of Technical Operations |
| Ms. Ashlee Dunston | Director of Investor Relations & Corporate Communications |
| Mr. Peter Villiger | Vice President of Corporate Development |
| Ms. Danielle Campbell | VP of Human Resource |
| Dr. Leslie Nangle Ph.D. | Vice President of Research |
| Dr. Ying J. Buechler Ph.D. | Executive Director of Biologics Development & Manufacturing |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7647 |
| Price-to-Sales TTM: | 244.9197 |
| IPO Date: | 2015-05-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 56 |